New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
07:55 EDTATRS, ATRS, BDX, BDX, ANTH, ANTH, NKTR, NKTR, SSH, SSH, IDRA, IDRA, LXRX, LXRX, ARAY, ARAY, ABBV, ABBV, INFI, INFI, JAZZ, JAZZ, IMMU, IMMUCowen to host a conference
34th Annual Global Healthcare Conference is being held in Boston on March 3-5 with webcasted company presentations to begin on March 5 at 8:00 am; not all company presentations may be webcasted. Webcast Link
News For ATRS;JAZZ;INFI;ABBV;ARAY;LXRX;IDRA;SSH;NKTR;ANTH;BDX;IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 26, 2015
07:09 EDTIDRAVertex, Novavax among select biotechs to buy on weakness, says Piper Jaffray
Subscribe for More Information
August 25, 2015
19:34 EDTABBVExperts tell White House to expand use of Hepatitis C drugs, NYT says
Health care experts from the Public Health Service and the Advisory Council on H.I.V./AIDS have recommended that Medicaid officials expand the use of costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni, reports the New York Times, citing correspondence sent to the White House. The advisory council said current usage limitations on the drugs are "unreasonable," but it also suggested that manufacturers disclose drug development costs in the face of the significant price tags on modern Hepatitis C treatments. Reference Link
16:09 EDTBDXBecton Dickinson unit acquires Cellular Research to develop genomics platform
Subscribe for More Information
09:03 EDTABBVAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
07:29 EDTBDXBecton Dickinson acquisition positive, says Stifel
Subscribe for More Information
August 24, 2015
18:55 EDTJAZZOn The Fly: After Hours Movers
Subscribe for More Information
18:52 EDTJAZZJazz, Celgene, Shire up after USPTO rejects Acorda patent challenge
Subscribe for More Information
August 21, 2015
09:13 EDTARAYOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Accuray (ARAY), up 12.7%... Brocade (BRCD), up 6%... salesforce.com (CRM), up 3.5%. DOWN AFTER EARNINGS: Intuit (INTU), down 6.7%... Deere (DE), down 5.4%... Nordson (NDSN), down 4.4%. ALSO LOWER: GigOptix (GIG), down 20% after 9.22M share Spot Secondary priced at $1.70... VirnetX Holding (VHC), down 19.8% after filing to sell 35M shares of common stock... Northwest Biotherapeutics (NWBO), down 8.7% after TheStreet's Adam Feuerstein reports, via Twitter, that CVax Phase 3 study has been temporarily halted in Germany.
06:01 EDTARAYAccuray awarded multi-system order by 21st Century Oncology
Subscribe for More Information
August 20, 2015
19:02 EDTARAYOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTARAYAccuray sees FY16 revenue $395M-$410M, consensus $408.39M
Subscribe for More Information
16:04 EDTARAYAccuray reports Q4 EPS (7c), consensus (4c)
Subscribe for More Information
14:42 EDTARAYNotable companies reporting after market close
Subscribe for More Information
August 19, 2015
17:45 EDTIMMUImmunomedics reports Q4 EPS (13c), consensus (13c)
Reports Q4 revenue $2.4M, one estimate $1.13M.
06:09 EDTABBVUnited Therapeutics agrees to sell PPRV to AbbVie for $350M
United Therapeutics (UTHR) announced that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher, or PPRV, to a subsidiary of AbbVie (ABBV). United Therapeutics received the PPRV when Unituxin was approved by the FDA for the treatment of neuroblastoma, a rare pediatric disease. Upon closing of the transaction, United Therapeutics will receive $350M in cash in exchange for the PPRV. The voucher was awarded by the FDA under a provision that encourages development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.
06:08 EDTBDXFDA warns 'do not use' compounded drugs stored in BD 3ml, 5ml syringes
Subscribe for More Information
05:57 EDTABBVAbbVie implied volatility of 20 at lower end of index mean range
August 18, 2015
07:07 EDTIMMUImmunomedics issued new U.S. patent
Subscribe for More Information
August 17, 2015
10:10 EDTARAYHigh option volume stocks
Subscribe for More Information
06:22 EDTIDRAPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use